Back to Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 4

Antimicrobial biocides in the healthcare environment: efficacy, usage, policies, and perceived problems

Authors Jean-Yves Maillard

Published 15 December 2005 Volume 2005:1(4) Pages 307—320

Jean-Yves Maillard

Welsh School of Pharmacy, Cardiff University, Cardiff, Wales, UK

Abstract: Biocides are heavily used in the healthcare environment, mainly for the disinfection of surfaces, water, equipment, and antisepsis, but also for the sterilization of medical devices and preservation of pharmaceutical and medicinal products. The number of biocidal products for such usage continuously increases along with the number of applications, although some are prone to controversies. There are hundreds of products containing low concentrations of biocides, including various fabrics such as linen, curtains, mattresses, and mops that claim to help control infection, although evidence has not been evaluated in practice. Concurrently, the incidence of hospital-associated infections (HAIs) caused notably by bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) remains high. The intensive use of biocides is the subject of current debate. Some professionals would like to see an increase in their use throughout hospitals, whereas others call for a restriction in their usage to where the risk of pathogen transmission to patients is high. In addition, the possible linkage between biocide and antibiotic resistance in bacteria and the role of biocides in the emergence of such resistance has provided more controversies in their extensive and indiscriminate usage. When used appropriately, biocidal products have a very important role to play in the control of HAIs. This paper discusses the benefits and problems associated with the use of biocides in the healthcare environment and provides a constructive view on their overall usefulness in the hospital setting.

Keywords: biocides, efficacy, resistance, healthcare

Download Article [PDF] 

Readers of this article also read:

The reasons for triple therapy in stable COPD patients in Japanese clinical practice

Miyazaki M, Nakamura H, Takahashi S, Chubachi S, Sasaki M, Haraguchi M, Terai H, Ishii M, Fukunaga K, Tasaka S, Soejima K, Asano K, Betsuyaku T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1053-1059

Published Date: 4 June 2015

Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study

Braz Júnior DS, Dornelas de Andrade A, Teixeira AS, Cavalcanti CA, Morais AB, Marinho PE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:125-132

Published Date: 12 January 2015

Visceral obesity is not an independent risk factor of mortality in subjects over 65 years

Thomas F, Pannier B, Benetos A, Vischer UM

Vascular Health and Risk Management 2013, 9:739-745

Published Date: 22 November 2013

Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11

Santos DM, Carneiro MW, de Moura TR, Fukutani K, Clarencio J, Soto M, Espuelas S, Brodskyn C, Barral A, Barral-Netto M, de Oliveira CI

International Journal of Nanomedicine 2012, 7:2115-2127

Published Date: 24 April 2012

Is reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization?

Nicola G Ghazi, Brian P Conway, James S Tiedeman, Steven J Yoon

Clinical Ophthalmology 2008, 2:773-780

Published Date: 5 December 2008

A thyrotoxicosis outbreak due to dietary pills in Paris

Vincent Ioos, Vincent Das, Eric Maury, Jean-Luc Baudel, Jérôme Guéchot, et al

Therapeutics and Clinical Risk Management 2008, 4:1375-1379

Published Date: 5 December 2008

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results

Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, et al

Therapeutics and Clinical Risk Management 2007, 3:569-578

Published Date: 15 September 2007

Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4

Shufeng Zhou, Eli Chan, Xiaotian Li, Min Huang

Therapeutics and Clinical Risk Management 2005, 1:3-13

Published Date: 15 April 2005